14.79  -0.01 (-0.07%)		10-14 16:00
Open: 14.77 High: 14.81 Volume: 2,512,763		Pre. Close: 14.8 Low: 14.77 Market Cap: 2,193(M)

Short term
Mid term
Targets	6-month :	17.59	1-year :	20.54
Resists	First :	15.06	Second :	17.59
Pivot price	14.77
Supports	First :	10.59	Second :	7.83
MAs	MA(5) :	14.81	MA(20) :	14.45
	MA(100) :	10.58	MA(250) :	9.16
MACD	MACD :	1.1	Signal :	1.2
%K %D	K(14,3) :	49.6	D(3) :	51
RSI	RSI(14): 77.3
52-week	High :	15.06	Low :	4.15

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ETNB ] has closed below upper band by 45.1%. Bollinger Bands are 90.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	14.84 - 14.92	14.92 - 14.98
Low:	14.56 - 14.66	14.66 - 14.75
Close:	14.65 - 14.8	14.8 - 14.93

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Wed, 08 Oct 2025
Inside INdiana Business - FinancialContent

Tue, 07 Oct 2025
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ETNB, TRML, CORZ, BRNS on Behalf of Shareholders - Morningstar

Tue, 30 Sep 2025
89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal - Yahoo Finance

Tue, 23 Sep 2025
Assenagon Asset Management S.A. Has $21.32 Million Stock Position in 89BIO $ETNB - MarketBeat

Tue, 23 Sep 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB) - PR Newswire

Thu, 18 Sep 2025
Why Did 89bio Stock Nearly Double In Value Today? - Stocktwits

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	148 (M)
Shares Float	95 (M)
Held by Insiders	0.5 (%)
Held by Institutions	103.5 (%)
Shares Short	8,720 (K)
Shares Short P.Month	16,380 (K)

EPS	-3.7
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.51
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-49.1 %
Return on Equity (ttm)	-86.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.14
Qtrly Earnings Growth	0 %
Operating Cash Flow	-439 (M)
Levered Free Cash Flow	-258 (M)

PE Ratio	-4.01
PEG Ratio	0
Price to Book value	4.2
Price to Sales	0
Price to Cash Flow	-5.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.